Since our inception in 2021, Anbio Biotechnology has been dedicated to advancing medical technology and providing innovative in vitro diagnostics (IVD) products. Our mission is to transform the diagnostics landscape globally, driving a shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to enhance patient outcomes and contribute to the improvement of healthcare worldwide.
Our extensive portfolio includes a diverse range of IVD products designed to meet various diagnostic needs. We offer solutions for over-the-counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting.
Our IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. In our current portfolio, we feature five IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). By providing advanced diagnostic capabilities, we empower healthcare professionals to identify and monitor various conditions, enabling timely intervention and improved patient care. Additionally, our IVD products are compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients.
Since our inception in 2021, Anbio Biotechnology has been dedicated to advancing medical technology and providing innovative in vitro diagnostics (IVD) products. Our mission is to transform the diagnostics landscape globally, driving a shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to enhance patient outcomes and contribute to the improvement of healthcare worldwide.
Our extensive portfolio includes a diverse range of IVD products designed to meet various diagnostic needs. We offer solutions for over-the-counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting.
Our IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. In our current portfolio, we feature five IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). By providing advanced diagnostic capabilities, we empower healthcare professionals to identify and monitor various conditions, enabling timely intervention and improved patient care. Additionally, our IVD products are compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients.